Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease

Background: The critical role of neuro-inflammation and oxidative stress in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) has become evident. Objective: The aim of this study is to assess the influence of vitamin supplementation on parameters of oxidative stress, inflammation as well as on cognition in patients with AD and mild cognitive impairment. Methods: In our study, patients with cognitive impairment and healthy controls were enrolled. All patients were intended to receive vitamin supplementation (vitamin B-1, B-6, B-12 and folic acid) for 3 months. Mini Mental State Examination (MMSE) and laboratory markers [carbonyl proteins (CPs), malondialdehyde, tryptophan (Trp), kynurenine (Kyn), neopterin, folic acid, vitamin B-12 level] were assessed for patients and controls at baseline and after 3 months. After half of the patients had been treated for 3 months, analyses were performed resulting in 3 subgroups: healthy controls without supplementation (15 subjects, 11 females), patients with vitamin supplementation (17 subjects, 10 females) and patients without vitamin supplementation (16 subjects, 9 females; baseline values prior to supplementation). Results: Age was significantly higher for the supplemented group (76.4 +/- 6.7 years) compared to vitamin-naive patients (63.3 +/- 13.7 years; p < 0.01). The MMSE score was higher in the supplemented group (23.1 +/- 4.8 vs. 20.3 +/- 9.5) but did not reach significance. Levels of CPs were significantly higher in the vitamin-na ve patients (p < 0.05). Levels of Kyn and the Kyn/Trp ratio were significantly lower in vitamin-na ve patients compared to the supplemented group (p < 0.05). No significant difference was seen for the other markers. Conclusion: Vitamin supplementation leads to reduced levels of CPs in patients. Pearson's correlation coefficient shows a negative relation (r = 0.69) between CPs and MMSE. Future trials should assess whether CPs might be suitable markers for monitoring of demented patients. (C) 2015 S. Karger AG, Basel